For full session details and more insights into the summit, explore the full 2025 event guide:
Conference Day Two
Thursday 16th October 2025
9:00 am Chair’s Opening Remarks
Discovering New Biomarkers to Uncover the Power of Emerging Therapeutics
9:15 am Leveraging Novel MS Biomarkers to Decode Disease Heterogeneity & Treatment Response for Precision Therapeutic Development
Synopsis
- Identifying novel MS biomarkers to predict individual risk, enabling personalized prevention strategies
- Validating progression-linked biomarkers that track disease severity, to optimize treatment timing and selection
- Linking biomarkers to therapeutic response for emerging drugs to accelerate clinical trial success and approval
9:45 am Discovering New Techniques to Measure Biomarkers in Spatial Models to Retain the Complex Cell-to-Cell Interactions while Predicting Effect
Synopsis
- Determining real-time longitudinal assays with high sensitivity and signal-to-noise ratios to capture temporal changes in complex spatial models
- Addressing the potential for spatial omics and histopathology of different models to measure biomarkers while preserving cellular architecture
- Developing new methods for multi-timepoint biomarker detection to bridge traditional endpoints with spatial biology workflows
10:15 am Morning Refreshment Break & Networking
11:00 am Solving the Model-to-Human Biomarker Disparity to Validate Drug Response
Synopsis
- Evaluating the model biomarker readouts and human biomarker correlation to reliably predict human clinical response
- Tackling the heterogeneric nature of autoimmune diseases to appreciate the biological influence towards biomarker discovery
- Validating the reliability of preclinical biomarkers to verify the therapeutic efficacy
Leveraging Innovative Models to Understand Disease Mechanisms
11:30 am Interactive Workshop: Reducing Mechanistic Biases for Autoimmune & Inflammatory Models to Maximize Accuracy of Model Translatability
Synopsis
- Evaluating the current approach to eliciting autoimmune pathology in models to highlight better methods of inducing autoimmune models
- Highlighting experiences of correct depictions of autoimmune pathology to improve model translatability
- Exploring novel approaches to inducing autoimmune models to counteract current industry biases
1:00 pm Lunch Break & Networking
2:15 pm Attenuating Immunogenicity During Preclinical Drug Testing to Provide Reliable Results
2:30 pm Dampening Immunogenicity of a Non-Human Protease to Induce Rapid, Deep & Sustained Catalytic Degradation of IgG in Autoimmune Disease
Synopsis
- Training of accurate AI tools for immunogenicity engineering using Big Data mutational scans of HLA class II epitopes
- Development of a bacterial IgG protease that rapidly and durably depletes antibodies in an animal models with quiet immunogenicity
- Treatment of autoimmune disease in animal models that mimic autoantibody-driven disease in humans
3:00 pm Engineering Non-Human Proteins with Machine Learning to Reduce Immunogenicity
Synopsis
- Demonstrate how AI-driven platforms can redesign bacterial-derived proteins to reduce immunogenicity and enhance therapeutic potential
- Validating assays and strategies to reliably evaluate immunogenicity risks during drug development
- Removing T-cell and B-cell epitopes to tackle stability and manufacturability